8-K: Exelixis Reports Strong Q1 2025 Results, Raises Full-Year Revenue Guidance by $100 Million

Exelixis announces impressive first quarter 2025 financial results, driven by CABOMETYX demand, and increases its full-year revenue guidance by $100 million.

Summary

• Exelixis reported total revenues of $555.4 million for the first quarter of 2025, compared to $425.2 million for the same period in 2024.
• Net product revenues were $513.3 million, up from $378.5 million in the first quarter of 2024, driven by increased sales volume and average net selling price.
• Collaboration revenues decreased to $42.2 million from $46.7 million year-over-year, primarily due to lower royalty revenues from cabozantinib sales outside the U.S.
• Research and development expenses decreased to $212.2 million from $227.7 million year-over-year.
• Selling, general, and administrative expenses increased to $137.2 million from $114.0 million year-over-year.
• GAAP net income was $159.6 million ($0.55 per diluted share), compared to $37.3 million ($0.12 per diluted share) in the first quarter of 2024.
• Non-GAAP net income was $179.6 million ($0.62 per diluted share), compared to $52.0 million ($0.17 per diluted share) in the first quarter of 2024.
• Exelixis increased its 2025 full-year total revenue guidance to $2.25 billion $2.35 billion, up from the previous guidance of $2.15 billion $2.25 billion.
• The company also increased its 2025 net product revenue guidance to $2.05 billion $2.15 billion, up from $1.95 billion $2.05 billion.
• CABOMETYX received FDA approval for previously treated advanced neuroendocrine tumors (NET).
• Exelixis is progressing with the development of zanzalintinib, with pivotal trial readouts expected in the second half of 2025.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, increased revenue guidance, and regulatory approval for CABOMETYX. The progress in the development of zanzalintinib further contributes to the positive sentiment.

Positives

• Strong financial performance in Q1 2025, driven by CABOMETYX demand.
• Increased full-year revenue guidance reflects confidence in continued growth.
• FDA approval of CABOMETYX for previously treated advanced NET expands its market potential.
• Progress in the development of zanzalintinib with anticipated pivotal trial readouts.
• Stock repurchase program demonstrates commitment to returning value to shareholders.
• CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated NET regardless of primary tumor site, grade, somatostatin receptor expression and functional status.

Negatives

• Collaboration revenues decreased due to lower royalty revenues from cabozantinib sales outside the U.S.
• Selling, general, and administrative expenses increased, primarily due to personnel, corporate giving, and marketing expenses.

Risks

• Market acceptance of CABOMETYX and other Exelixis products may vary.
• The effectiveness of CABOMETYX and other Exelixis products may be challenged by competing products.
• Clinical trials for cabozantinib, zanzalintinib, and other product candidates may not demonstrate safety and/or efficacy.
• Regulatory review and approval processes are complex and unpredictable.
• Unexpected safety concerns or data analyses may arise from clinical trials.
• Exelixis depends on third-party vendors for the development, manufacture, and supply of its products and product candidates.
• Market competition, including the potential for competitors to obtain approval for generic versions of Exelixis marketed products, could impact revenue.

Future Outlook

Exelixis anticipates pivotal trial readouts for zanzalintinib in the second half of 2025 and plans to initiate the STELLAR-311 pivotal study in neuroendocrine tumors in the first half of the year. The company also expects Merck to initiate two pivotal studies evaluating zanzalintinib and belzutifan in renal cell carcinoma.

Management Comments

• Michael M. Morrissey, Ph.D., President and Chief Executive Officer, stated that Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX demand, new patient starts and revenues.
• Dr. Morrissey also mentioned that based on the strong first quarter dynamics of CABOMETYX, they are increasing their 2025 full year financial guidance for net product revenues and total revenues by $100 million.
• Dr. Morrissey noted that the Exelixis commercial team rapidly mobilized for the launch of CABOMETYX in advanced neuroendocrine tumors (NET) within hours of receiving U.S. regulatory approval in late March and that they are very pleased with the initial reception.
• Dr. Morrissey stated that as they work toward their goal of becoming a multi-franchise oncology company, they look forward to important potential milestones for zanzalintinib in the second half of 2025, based on anticipated event rates.

Industry Context

Exelixis' focus on oncology and its development of CABOMETYX and zanzalintinib align with the broader industry trend of developing targeted therapies for various cancer types. The FDA approval of CABOMETYX for previously treated advanced NET positions Exelixis as a key player in the neuroendocrine tumor treatment landscape.

Comparison to Industry Standards

• Exelixis' revenue growth and profitability compare favorably to other oncology-focused biopharmaceutical companies such as Incyte and BeiGene.
• The company's CABOMETYX franchise competes with other tyrosine kinase inhibitors (TKIs) in the renal cell carcinoma and neuroendocrine tumor markets, such as Pfizer's Sutent and Novartis' Afinitor.
• The development of zanzalintinib as a potential treatment for colorectal cancer and renal cell carcinoma places Exelixis in competition with companies developing similar targeted therapies and immunotherapies, such as Bristol Myers Squibb and Merck.
• The stock repurchase program is a common practice among mature biopharmaceutical companies with strong cash flow, similar to Amgen and Gilead Sciences.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance, increased revenue guidance, and stock repurchase program.
• Employees will benefit from the company's growth and success.
• Patients will benefit from the availability of new and improved cancer treatments.
• Suppliers and partners will benefit from the company's continued operations and growth.
• Creditors will benefit from the company's strong financial position.

Next Steps

• Exelixis plans to continue the development of zanzalintinib, with pivotal trial readouts expected in the second half of 2025.
• The company anticipates initiating the STELLAR-311 pivotal study in neuroendocrine tumors in the first half of the year.
• Exelixis expects Merck to initiate two pivotal studies evaluating zanzalintinib and belzutifan in renal cell carcinoma.
• The company plans to submit an IND application for XB371 to the FDA in 2025.
• Exelixis will present data at ASCO 2025.

Key Dates

Keywords

Exelixis, CABOMETYX, Zanzalintinib, Financial Results, Q1 2025, Revenue Guidance, Net Product Revenues, FDA Approval, Neuroendocrine Tumors, Stock Repurchase, Oncology